AUS
NZ
UK
CA
USA
IND
ImpediMed Limited (ASX:IPD) has informed the ASX that 2,635,000 unquoted options (IPDAAB) expired on 30 June 2026 following the lapse of conditional rights. These options, which had varying exercise prices and expiry dates, ceased due to failure to meet the attached conditions. Despite this lapse, the company’s issued capital structure remains largely unchanged, with ordinary shares and other option classes continuing to trade and remain outstanding.
Key Highlights
- ImpediMed Limited (IPD) is a medical device company listed on the ASX.
- The company reported the cessation of 2,635,000 unquoted options (IPDAAB) due to lapse of conditional rights.
- These options expired on 30 June 2026 after the conditions tied to their issuance were not fulfilled or became impossible to satisfy.
- Post-cessation, ImpediMed holds 3,662,493,691 ordinary fully paid shares and multiple classes of quoted and unquoted securities.
- No consideration was paid by the company for the options’ lapse.
ImpediMed’s Capital Structure and Market Presence
ImpediMed Limited (ABN 65 089 705 144) is an ASX-listed company with a diversified capital structure that includes both quoted and unquoted securities. Its portfolio encompasses various equity instruments and options designed to support strategic goals and operational needs. As of the 20 July 2026 update, the company’s capitalisation includes ordinary fully paid shares actively traded on the ASX, alongside multiple option and warrant classes in both quoted and unquoted forms.
The lapse of the IPDAAB options reflects a routine adjustment to the company’s issued capital. These unquoted options were not tradable on the ASX but formed part of ImpediMed’s broader equity incentive framework, commonly used in employee share schemes, strategic partnerships, or performance-based compensation plans where vesting depends on meeting specific conditions.
Reasons Behind the Lapse of 2.6 Million Options
The 2,635,000 IPDAAB options expired because the conditional rights attached to them were either unmet or became impossible to satisfy by 30 June 2026. These options were issued with performance targets or contractual milestones that had to be achieved for vesting or validity. Failure to meet these conditions results in automatic lapse, rendering the options void.
The announcement does not specify which conditions were unmet, but such provisions typically relate to revenue goals, operational milestones, stock price targets, or other performance metrics. The absence of any consideration paid to option holders confirms this was a contractual expiration rather than a negotiated buyback or settlement.
Remaining Unquoted Options and Warrants After Expiry
Following the lapse of the 2,635,000 IPDAAB options, ImpediMed continues to hold 36,767,250 other IPDAAB options, indicating that this expired tranche was distinct from other outstanding options within the same class. This suggests a structured approach with multiple tranches linked to different vesting schedules or performance periods.
Additionally, the company holds 1,800,000,000 IPDAD options expiring 31 December 2027 at an exercise price of $0.015, 18,737,805 IPDAB warrants, and 7,335,466 performance rights. This layered equity structure supports various strategic objectives such as employee incentives, funding, and partnerships, reflecting active capital management.
Quoted Securities and Overall Issued Capital
ImpediMed’s quoted securities remain stable, with 3,662,493,691 ordinary fully paid shares (IPD) outstanding as of the announcement date. These shares constitute the company’s primary equity and are central to market capitalisation calculations used by the ASX for regulatory and indexation purposes.
The company also maintains a significant quoted options class, IPDO options, with 1,800,000,000 options expiring 31 March 2027. This large quoted options pool indicates active investor interest in derivative securities related to ImpediMed’s shares, offering varied risk-return profiles.
Administrative and Compliance Details of the Option Lapse
The lapse of these options was processed through the ASX Appendix 3H notification, fulfilling ImpediMed’s continuous disclosure obligations. The filing detailed the security code (IPDAAB), number of options affected (2,635,000), reason for cessation (lapse of conditional rights), and effective date (30 June 2026).
The company confirmed no consideration was paid for the lapse, indicating a straightforward contractual expiration without cash settlement or alternative compensation, thereby minimizing administrative complexity and shareholder dilution concerns.
Impact on Issued Capital and Market Capitalisation
The expiry of 2,635,000 IPDAAB options represents a minor reduction in the total issued capital. While this marginally lowers the fully diluted share count, the ordinary shares remain the primary driver of market capitalisation and corporate actions.
ImpediMed’s equity incentive framework, including performance-based option vesting, is functioning as intended. The lapse of certain option tranches due to unmet conditions is typical for mature ASX-listed companies and does not necessarily indicate operational or strategic issues.
Comparison of Expired and Remaining Option Classes
The expired 2,635,000 IPDAAB options appear to be an earlier tranche distinct from the 36,767,250 IPDAAB options still outstanding. This reflects a staggered issuance strategy with different vesting and performance conditions. The company also holds the IPDAD options class (1,800,000,000 options expiring 31 December 2027 at $0.015 exercise price), which is separate from IPDAAB, allowing granular management of incentive programs aligned with various business objectives.
Regulatory Disclosure and Transparency
ImpediMed’s timely Appendix 3H filing ensures compliance with ASX continuous disclosure requirements, providing investors with detailed information on security changes, reasons for cessation, and updated capital structure. This transparency supports accurate valuation and governance.
The lapse of unquoted options due to unmet conditions is generally viewed neutrally or positively by the market, as it reduces potential future dilution. The lack of consideration paid further supports this view, confirming the lapse was a contractual event rather than a value transfer.
Investor Considerations Moving Forward
Investors should monitor ImpediMed’s ongoing equity management, including exercise activity of the substantial remaining options and warrants. Notably, 1,800,000,000 quoted IPDO options expire in March 2027, and 1,800,000,000 unquoted IPDAD options expire in December 2027, which could lead to increased share issuance and dilution depending on exercise prices relative to market values.
Additionally, tracking the satisfaction or lapse of conditions tied to other unquoted option classes and any changes in performance rights (currently 7,335,466 outstanding) is important, as these are linked to operational and financial milestones critical to ImpediMed’s strategic execution.
